Shares of St. Jude Medical, Inc. (STJ) hit a new 52-week low on Thursday. The stock traded as low as $33.52 during mid-day trading and last traded at $33.59. The stock previously closed at $33.79.
A number of equities research firms have also recently weighed in on the stock. Analysts at Jefferies downgraded shares of St. Jude Medical from a “buy” rating to a “hold” rating in a research note to investors on Tuesday. They now have a $38.00 price target on the stock. Analysts at Citigroup (NYSE: C) reiterated a “sell” rating on shares of St. Jude Medical in a research note to investors on Friday, December 9th. They now have a $34.00 price target on the stock.
St. Jude Medical, Inc. (St. Jude) develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiology and cardiac surgery and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. St. Jude operates in four segments: Cardiac Rhythm Management (CRM), Cardiovascular (CV), Atrial Fibrillation (AF) and Neuromodulation (NMD). It markets and sells its products through both a direct sales force and independent distributors. The principal geographic markets for its products are the United States, Europe, Japan and Asia Pacific. In July 2010, it acquired LightLab Imaging, Inc. (LightLab Imaging). In November 2010, the Company acquired AGA Medical Holdings, Inc. (AGA Medical).
St. Jude Medical, Inc. has a 52 week low of $33.54 and a 52 week high of $54.18. The stock’s 50-day moving average is $37.4 and its 200-day moving average is $42.33. The company has a market cap of $10.718 billion and a price-to-earnings ratio of 12.29.
Stay ahead of the market with our daily email update that provides a summary of analysts' upgrades, downgrades and new coverage. Click here to register now.